Infantile hemangioma (IH) is the most common benign vascular tumor characterized by three phases - proliferation, early involution and late involution. Mast cells (MCs) play an important role in allergic reactions and numerous diseases, including tumors. While the mechanisms underlying MCs migration, activation and function in the life cycle of IH remain unclear, previous studies suggested that MCs circulate through the vasculature and migrate into IH, and subsequently mature and get activated. Estradiol (E2) emerges as a potential attractant for MC migration into IH and their subsequent activation. In various stages of IH, activated MCs secrete both proangiogenic and anti-angiogenic modulators, absorbed by various cells adjacent to them. Imbalances in these modulators may contribute to IH proliferation and involution.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10834664 | PMC |
http://dx.doi.org/10.3389/fonc.2024.1304478 | DOI Listing |
BMJ Case Rep
January 2025
Paediatric Department, SJOG Midland Public Hospital, Midland, Western Australia, Australia.
Infantile haemangiomas are a common presentation in infants within the first few months of life. The majority of haemangiomas are benign; however, large haemangiomas (≥5 cm), especially those involving the face, may indicate a more serious underlying neurocutaneous disorder known as PHACE (Posterior fossa malformations, Haemangioma, Arterial anomalies, Coarctation of the aorta/Cardiac defects and Eye abnormalities) syndrome. The authors report an unusual case of possible PHACE syndrome in a young male toddler with a large facial haemangioma.
View Article and Find Full Text PDFJACC Case Rep
December 2024
Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Fetal and neonatal cardiac tumors are rare and often benign. Clinical presentation is primarily related to mass effect, pericardial effusion or arrhythmia. Prenatal detection can assist with risk assessment and inform optimal delivery plan and postnatal management.
View Article and Find Full Text PDFJACC Case Rep
December 2024
Groupement de Coopération Sanitaire-Groupement des Hôpitaux de l'Institut Catholique de Lille/Lille Catholic Hospitals, Heart Valve Center, Cardiology Department, DATACARD (Données Arythmie Technologie et imAgerie CARDio-vasculaire), ETHICS (Experience, technology & human interactions, care & society) EA 7446, Lille Catholic University, Lille, France.
We present a case of a 76-year-old man with de novo right heart failure. Echocardiography initially detected a mass near to the posterior area of the right atrium. Despite a comprehensive multimodality imaging assessment, the exact location of the mass remained unclear.
View Article and Find Full Text PDFCureus
December 2024
Department of Pediatrics, Toranomon Hospital, Tokyo, JPN.
Background: Oral propranolol therapy is currently the first choice for infants with infantile hemangiomas (IHs) requiring systemic treatment. This study aims to evaluate the safety and effectiveness of oral propranolol therapy for IHs and to assess the role of a multidisciplinary medical team in supporting optimal treatment.
Materials And Methods: Clinical data were retrospectively reviewed from medical records in 150 Japanese infants with IH treated with propranolol orally at Toranomon Hospital.
Int J Surg Case Rep
January 2025
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia; Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address:
Introduction: Retinal capillary hemangioma (RCH) is a benign vascular hamartoma that can occur sporadically or as a manifestation of Von Hippel-Lindau (VHL) disease. If left untreated, it results in adverse ocular complications depending on its location and eventual visual loss.
Case Presentation: We present a 50-year-old man who was a known case of VHL with history of left eye vision loss in the left eye at the age of 30 years.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!